These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 28371641)

  • 1. Recent progress in the identification of selective butyrylcholinesterase inhibitors for Alzheimer's disease.
    Li Q; Yang H; Chen Y; Sun H
    Eur J Med Chem; 2017 May; 132():294-309. PubMed ID: 28371641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new therapeutic target in Alzheimer's disease treatment: attention to butyrylcholinesterase.
    Greig NH; Utsuki T; Yu Q; Zhu X; Holloway HW; Perry T; Lee B; Ingram DK; Lahiri DK
    Curr Med Res Opin; 2001; 17(3):159-65. PubMed ID: 11900310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of Butyrylcholinesterase with Fluorobenzylcymserine, An Experimental Alzheimer's Drug Candidate: Validation of Enzoinformatics Results by Classical and Innovative Enzyme Kinetic Analyses.
    Kamal MA; Shakil S; Nawaz MS; Yu QS; Tweedie D; Tan Y; Qu X; Greig NH
    CNS Neurol Disord Drug Targets; 2017; 16(7):820-827. PubMed ID: 28176640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of Novel Pyrazolopyrimidinone Derivatives as Phosphodiesterase 9A Inhibitors Capable of Inhibiting Butyrylcholinesterase for Treatment of Alzheimer's Disease.
    Yu YF; Huang YD; Zhang C; Wu XN; Zhou Q; Wu D; Wu Y; Luo HB
    ACS Chem Neurosci; 2017 Nov; 8(11):2522-2534. PubMed ID: 28783948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective inhibitors of butyrylcholinesterase: a valid alternative for therapy of Alzheimer's disease?
    Giacobini E
    Drugs Aging; 2001; 18(12):891-8. PubMed ID: 11888344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.
    Andrisano V; Naldi M; De Simone A; Bartolini M
    Expert Opin Ther Pat; 2018 Jun; 28(6):455-465. PubMed ID: 29757691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kinetics of human serum butyrylcholinesterase inhibition by a novel experimental Alzheimer therapeutic, dihydrobenzodioxepine cymserine.
    Kamal MA; Klein P; Luo W; Li Y; Holloway HW; Tweedie D; Greig NH
    Neurochem Res; 2008 May; 33(5):745-53. PubMed ID: 17985237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cholinesterases: new roles in brain function and in Alzheimer's disease.
    Giacobini E
    Neurochem Res; 2003 Apr; 28(3-4):515-22. PubMed ID: 12675140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting acetylcholinesterase and butyrylcholinesterase in dementia.
    Lane RM; Potkin SG; Enz A
    Int J Neuropsychopharmacol; 2006 Feb; 9(1):101-24. PubMed ID: 16083515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Butyrylcholinesterase: an important new target in Alzheimer's disease therapy.
    Greig NH; Lahiri DK; Sambamurti K
    Int Psychogeriatr; 2002; 14 Suppl 1():77-91. PubMed ID: 12636181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Status of acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease and type 2 diabetes mellitus.
    Mushtaq G; Greig NH; Khan JA; Kamal MA
    CNS Neurol Disord Drug Targets; 2014; 13(8):1432-9. PubMed ID: 25345511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Highly selective inhibition of butyrylcholinesterase by a novel melatonin-tacrine heterodimers.
    Zawadzka A; Lozińska I; Molęda Z; Panasiewicz M; Czarnocki Z
    J Pineal Res; 2013 May; 54(4):435-41. PubMed ID: 24325732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cholinesterase inhibition in Alzheimer's disease: is specificity the answer?
    Macdonald IR; Rockwood K; Martin E; Darvesh S
    J Alzheimers Dis; 2014; 42(2):379-84. PubMed ID: 24898642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of human cholinesterases by drugs used to treat Alzheimer disease.
    Darvesh S; Walsh R; Kumar R; Caines A; Roberts S; Magee D; Rockwood K; Martin E
    Alzheimer Dis Assoc Disord; 2003; 17(2):117-26. PubMed ID: 12794390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kinetic analysis of the inhibition of human butyrylcholinesterase with cymserine.
    Kamal MA; Al-Jafari AA; Yu QS; Greig NH
    Biochim Biophys Acta; 2006 Feb; 1760(2):200-6. PubMed ID: 16309845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cholinesterase inhibitors modify the activity of intrinsic cardiac neurons.
    Darvesh S; Arora RC; Martin E; Magee D; Hopkins DA; Armour JA
    Exp Neurol; 2004 Aug; 188(2):461-70. PubMed ID: 15246845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in the treatment of Alzheimer's disease: benefits of dual cholinesterase inhibition.
    Ballard CG
    Eur Neurol; 2002; 47(1):64-70. PubMed ID: 11803198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo butyrylcholinesterase activity is not increased in Alzheimer's disease synapses.
    Kuhl DE; Koeppe RA; Snyder SE; Minoshima S; Frey KA; Kilbourn MR
    Ann Neurol; 2006 Jan; 59(1):13-20. PubMed ID: 16278840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis and evaluation of novel ferulic acid-O-alkylamine derivatives as potential multifunctional agents for the treatment of Alzheimer's disease.
    Sang Z; Pan W; Wang K; Ma Q; Yu L; Yang Y; Bai P; Leng C; Xu Q; Li X; Tan Z; Liu W
    Eur J Med Chem; 2017 Apr; 130():379-392. PubMed ID: 28279845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective reversible inhibition of human butyrylcholinesterase by aryl amide derivatives of phenothiazine.
    Darvesh S; McDonald RS; Darvesh KV; Mataija D; Conrad S; Gomez G; Walsh R; Martin E
    Bioorg Med Chem; 2007 Oct; 15(19):6367-78. PubMed ID: 17681768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.